Expression of PD-L1, AR, and P53 in urothelial carcinoma and their correlation with clinical prognosis

Expression of PD-L1, AR, and P53 in urothelial carcinoma and their correlation with clinical prognosis

Objective This study aims to observe the expression of programmed cell death 1 ligand 1 (PD-L1), P53, and androgen receptor (AR) in tumor tissues of patients with urothelial carcinoma (UC) and analyze their correlation with patient prognosis. Methods A retrospective analysis was conducted on 115 UC...

Full description

Saved in:

Bibliographic Details
Main Author:	ZHOU Xiaodie, Qi Rongxin, WANG Xuan, YU Bo, WANG Jianjun, SHI Qunli, RAO Qiu, BAO Wei
Format:	Article
Language:	zho
Published:	Editorial Office of Journal of Diagnostics Concepts & Practice 2025-06-01
Series:	Zhenduanxue lilun yu shijian
Subjects:	\|urothelial carcinoma\|clinicopathology\|programmed cell death 1 ligand 1\|androgen receptor\|prognosis
Online Access:	https://www.qk.sjtu.edu.cn/jdcp/fileup/1671-2870/PDF/1756094091985-350834633.pdf
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Correlation of HER2 expression and clinicopathological characteristics in patients with urothelial carcinoma in China
by: WANG Shanshan, YE Dingwei, YANG Li, CHENG Fan, YANG Tiejun, ZHANG Xiaoping, YU Zhixian, ZHANG Qingyun, YANG Yong
Published: (2024-11-01)

PD-L1 expression and its association with clinicopathological and computed tomography features in surgically resected non-small cell lung cancer: a retrospective cohort study
by: Shiwei Wang, et al.
Published: (2025-07-01)

Assessment of PD-L1 expression in patients with neuroblastoma and renal tumors
by: Seher Şener, et al.
Published: (2021-10-01)

Therapeutic targeting of the androgen receptor (AR) and AR variants in prostate cancer
by: Ramesh Narayanan
Published: (2020-07-01)

Programmed death ligand 1 (PD-L1) expression in gastric cancer: literature review
by: T. N. Sotnikova, et al.
Published: (2023-07-01)

Co-expression and clinical utility of AR-FL and AR splice variants AR-V3, AR-V7 and AR-V9 in prostate cancer
by: Neele Wüstmann, et al.
Published: (2023-04-01)

Efficacy of PD-1/PD-L1 inhibitors in advanced hepatocellular carcinoma: A systematic review and meta-analysis
by: Tzu-Rong Peng, et al.
Published: (2023-11-01)

Distribution and clinicopathological characteristics of G-CSF expression in tumor cells and stromal cells in upper tract urothelial carcinoma
by: Go Kobayashi, et al.
Published: (2024-12-01)

Expression patterns of estrogen and androgen receptors in NSCLC patients according to the PD-L1 profile
by: Vianey Rodriguez-Lara, et al.
Published: (2025-06-01)

PD-L1 on Circulating Tumor Cells Indicates Poor Prognosis in Breast Cancer
by: Xue-fei Wang, et al.
Published: (2022-11-01)

The SPARC-related modular calcium binding 1 (Smoc1) regulated by androgen is required for mouse gubernaculum development and testicular descent
by: Zhi-Yi Zhao, et al.
Published: (2025-01-01)

RIP2/NF-κB/PD-L1 signaling pathway is involved in temozolomide resistance by inducing autophagy in glioblastoma cells
by: Xiaomeng Liu, et al.
Published: (2025-08-01)

Efficacy and safety of RC48 in combination with PD-1 inhibitors for the treatment of locally advanced or metastatic urothelial carcinoma: a single-center, real-world study
by: Tiantian Zhang, et al.
Published: (2025-04-01)

Androgen receptor in bladder cancer: A promising therapeutic target
by: Abhishek Tripathi, et al.
Published: (2020-07-01)

Accessing utility of immunohistochemistry, PD-L1 correlation with stage of cancer and EGFR mutation with disease survival in primary lung carcinoma
by: Kartavya Kumar Verma, et al.
Published: (2025-06-01)

CD4 T cells correlate with better prognosis in medulloblastoma
by: Jin Zhang, et al.
Published: (2025-06-01)

Efficacy and safety of neoadjuvant PD-1 inhibitors or PD-L1 inhibitors combined with chemoradiotherapy for locally advanced rectal cancer: a systematic review and meta-analysis
by: Jiaojiao Yu, et al.
Published: (2025-05-01)

The prognostic implications of podoplanin in cancer‐associated fibroblasts and PD‐L1 expression in high‐grade neuroendocrine carcinoma of the lung
by: Tatsuya Miyamoto, et al.
Published: (2024-12-01)

Nevi, dysplastic nevi, and melanoma: Molecular and immune mechanisms involving the progression
by: Wei-Wen Sung, et al.
Published: (2022-01-01)

Development and Validation of a Biolayer Interferometry Method for Determination of Human Anti-PD-1 Monoclonal Antibody Concentration in Cynomolgus Serum
by: K. V. Ulyanova, et al.
Published: (2020-12-01)

Efficacy comparison of PD-1/PD-L1 inhibitor monotherapy and combination with PARPis or antiangiogenic agents in advanced or recurrent endometrial cancer: a systematic review and network meta-analysis
by: Shiya Ji, et al.
Published: (2025-02-01)

Programmed Death Ligand 1 expression in Urothelial Carcinoma.A retrospective study in Duhok City-Iraq.
by: Zuzan Shawkat Mustafa, et al.
Published: (2024-06-01)

Clinicopathologic and prognosis of 30 patients with FH-deficient renal cell carcinoma: a single-center retrospective study
by: Junjie Bai, et al.
Published: (2025-07-01)

Safety and efficacy of oral cancer vaccine B440 in patients with PD-1/PD-L1 inhibitor-resistant advanced urothelial cancer: a study protocol for a phase 1 multicenter, open-label, single-arm clinical trial
by: Junya Furukawa, et al.
Published: (2025-02-01)

Coordinated AR and microRNA regulation in prostate cancer
by: Ieva Eringyte, et al.
Published: (2020-07-01)

Anti‐PD‐1 therapy redirects macrophages from an M2 to an M1 phenotype inducing regression of OS lung metastases
by: Pooja Dhupkar, et al.
Published: (2018-06-01)

Downregulation of PD-L1 expression by Wnt pathway inhibition to enhance PD-1 blockade efficacy in hepatocellular carcinoma
by: Yu-Yun Shao, et al.
Published: (2025-04-01)

PLUNC downregulates the expression of PD-L1 by inhibiting the interaction of DDX17/β-catenin in nasopharyngeal carcinoma
by: Ranran Feng, et al.
Published: (2025-01-01)

Recent advances in the mechanisms of PD-L1 expression in gastric cancer: a review
by: Peifeng Chen, et al.
Published: (2025-03-01)

A CT-based interpretable deep learning signature for predicting PD-L1 expression in bladder cancer: a two-center study
by: Xiaomeng Han, et al.
Published: (2025-03-01)

Functional circuits of LYL1 controlled by supraphysiological androgen in prostate cancer cells to regulate cell senescence
by: Mehdi Heidari Horestani, et al.
Published: (2024-12-01)

Effects of chemoradiotherapy on surface PD-L1 expression in esophageal cancer and its implications for immunotherapy
by: Lovis Hampe, et al.
Published: (2024-12-01)

Cancer cell membrane cloaking nanoparticles for targeted co-delivery of doxorubicin and PD-L1 siRNA
by: Mushi Chen, et al.
Published: (2019-12-01)

Relationship between puerarin and urothelial carcinoembryonic antigen 1 expression in apoptosis and autophagy of esophageal cancer cells
by: LI Jing, WANG Jumei, TIAN Jingrong, BI Lihua, GAO Yuanyuan, SHANG Hong
Published: (2025-01-01)

Expression of FOXM1 and PLK1 in Colorectal Cancer and Their Relationship with Clinicopathological Features and Prognosis
by: Xue HAN, et al.
Published: (2025-07-01)

Artificial Intelligence and Novel Technologies for the Diagnosis of Upper Tract Urothelial Carcinoma
by: Nikolaos Kostakopoulos, et al.
Published: (2025-05-01)

Genetic Alterations in Chromatin Regulatory Genes in Upper Tract Urothelial Carcinoma and Urothelial Bladder Cancer
by: Shuo Wang, et al.
Published: (2024-11-01)

Discovery and functional characterization of canine PD-L1-targeted antibodies for evaluating antitumor efficacy in a canine osteosarcoma xenograft model
by: Min-young Song, et al.
Published: (2025-03-01)

Assessment of programmed cell death 1 and its programmed cell death ligand 1 levels in vitiligo
by: Hanan R. Nada, et al.
Published: (2025-01-01)

Correlation between HMGB1 expression and drug resistance and prognosis in patients with bladder urothelial carcinoma
by: Min Xu, et al.
Published: (2025-05-01)